Hui-qiong ZHOU, Feng-chun ZHANG. The Value of Krebs von den Lungen-6 in the Clinical Management of Interstitial Lung Diseases[J]. Medical Journal of Peking Union Medical College Hospital, 2018, 9(3): 207-212. doi: 10.3969/j.issn.1674-9081.2018.03.004
Citation: Hui-qiong ZHOU, Feng-chun ZHANG. The Value of Krebs von den Lungen-6 in the Clinical Management of Interstitial Lung Diseases[J]. Medical Journal of Peking Union Medical College Hospital, 2018, 9(3): 207-212. doi: 10.3969/j.issn.1674-9081.2018.03.004

The Value of Krebs von den Lungen-6 in the Clinical Management of Interstitial Lung Diseases

doi: 10.3969/j.issn.1674-9081.2018.03.004
More Information
  • Corresponding author: ZHANG Feng-chun Tel: 010-69155007, Email: zhangfccra@aliyun.com
  • Received Date: 2018-04-03
  • Publish Date: 2018-05-30
  • Interstitial lung diseases (ILDs) are a group of diverse pulmonary disorders characterized by various patterns of inflammation and fibrosis in the interstitium of the lung. There are no specific diagnostic methods for ILDs currently and various serum biomarkers, including Krebs von den Lungen-6 (KL-6), have been tested for their use in diagnosing ILDs. However, the pathophysiological role of KL-6 in patients with ILDs is not yet very clear. KL-6 is high-molecular-weight glycoprotein and moderately expressed in type Ⅱ pneumocytes and respiratory bronchiolar epithelial cells. KL-6 has been found to have an association with various types of diseases such as cancers, some neonatal lung diseases, ILDs, and acute lung injury. In this article, we review the structure of KL-6 and the relationship between the elevation of KL-6 and the etiology, progression, treatment evaluation, and prognosis of ILDs.
  • loading
  • [1] Tzouvelekis A, Kouliatsis G, Anevlavis S, et al. Serum biomarkers in interstitial lung diseases[J]. Respir Res, 2005, 6:1-24. doi:  10.1186/1465-9921-6-1
    [2] Ishikawa N, Hattori N, Yokoyama A, et al. Utility of KL-6/MUC1 in the clinical management of interstitial lung diseases[J]. Respir Investig, 2012, 50:3-13. doi:  10.1016/j.resinv.2012.02.001
    [3] Kohno N, Akiyama M, Kyoizumi S, et al. Detection of soluble tumor-associated antigens in sera and effusions using novel monoclonal antibodies, KL-3 and KL-6, against lung adenocarcinoma[J]. Jpn J Clin Oncol, 1988, 18:203-216. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=HighWire000005639932
    [4] Stahel RA, Gilks WR, Lehmann HP, et al.Third International Work shop on Lung Tumor and Differentiation Anti-gens:overview of the results of the central data analysis[J].Int J Cancer(Suppl), 1994, 8:6-26. http://www.onacademic.com/detail/journal_1000033846762610_85d3.html
    [5] Ohtsuki Y, Fujita J, Hachisuka Y, et al, Immunohistochemical and immunoelectron microscopic studies of the localization of KL-6 and epithelial membrane antigen(EMA)in presumably normal pulmonary tissue and in interstitial pneumonia[J].Med Mol Morphol, 2007, 40:198-202. doi:  10.1007/s00795-007-0382-7
    [6] Hattrup CL, Gendier SJ.Structure and function of the cell surface (tethered) mucins[J].Annu Rev Physiol, 2008, 70:431-457. doi:  10.1146/annurev.physiol.70.113006.100659
    [7] DoiM, Yokoyama A, Kondo K, et al.Anti-tumor effect of the anti-KL-6/MUC1 monoclonal antibody through exposure of surface molecules by MUCl capping[J].Cancer Sci, 2006, 97:420-429. doi:  10.1111/j.1349-7006.2006.00183.x
    [8] Hirasawa Y, Kohno N, Yokoyama A, et al.KL-6, a human MUCl mucin, is chemotactic for human fibroblasts[J].Am J Respir Cell Mol Biol, 1997, 17:501-507. doi:  10.1165/ajrcmb.17.4.2253
    [9] Kohno N, Kyoizumi S, Awaya Y, et al. New serum indicator of interstitial pneumonitis activity. Sialylated carbohydrate antigen KL-6[J]. Chest, 1989, 96:68-73. doi:  10.1378/chest.96.1.68
    [10] Xu L, Yan DR, Zhu SL, et al. KL-6 regulated the expression of HGF, collagen and myofibroblast differentiation[J]. Eur Rev Med Pharmacol Sci, 2013, 17:3073-3077. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=7c341d370b53f86b9f25fcff65fe997e
    [11] Ohshimo S, Yokoyama A, Hattori N, et al.KL-6, a human MUC1/mucin, promotes proliferation and survival of lung fibroblasts[J].Bio chem Biophys Res Commun, 2005, 338:1845-1852. doi:  10.1016/j.bbrc.2005.10.144
    [12] Xu L, Yang D, Zhu S, et al. Bleomycin-induced pulmonary fibrosis is attenuated by an antibody against KL-6[J]. Experimental Lung Research, 2013, 39, 241-248. doi:  10.3109/01902148.2013.798056
    [13] Shimizu Y, Kuwabara H, Ono A, et al. Intracellular Th1/Th2 balance of pulmonary CD4(+) T cells in patients with active interstitial pneumonia evaluated by serum KL-6[J]. Immunopharmacol Immunotoxicol, 2006, 28:295-304. doi:  10.1080/08923970600809389
    [14] Ishikawa N, Hattori N, Yokoyama A, et al. Utility of KL-6/MUC1 in the clinical management of interstitial lung diseases[J]. Respir Investig, 2012, 50:3-13. doi:  10.1016/j.resinv.2012.02.001
    [15] Ohnishi H, Yokoyama A, Kondo K, et al. Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases[J]. Am J Respir Crit Care Med, 2002, 165:378-381. doi:  10.1164/ajrccm.165.3.2107134
    [16] 朱晨, 赵亚滨, 孔灵菲, 等.涎液化糖链抗原-6在不同类型的弥漫性间质性肺疾病患者血清和支气管肺泡灌洗液中的表达及临床意义[J].中华结核和呼吸杂志, 2016, 39:93-97. doi:  10.3760/cma.j.issn.1001-0939.2016.02.004
    [17] Sugaya A, Ishiguro S, Mitsuhashi S, et al. Interstitial lung disease associated with trastuzumab monotherapy:A report of 3 cases[J]. Mol Clin Oncol, 2017, 6:229-232. doi:  10.3892/mco.2016.1113
    [18] Miyata M, Sakuma F, Fukaya E, et al. Detection and monitoring of methotrexate-associated lung injury using serum markers KL-6 and SP-D in rheumatoid arthritis[J]. Intern Med, 2002, 41:467-473. doi:  10.2169/internalmedicine.41.467
    [19] 赵亚东, 李振华, 康健, 等.特发性肺纤维化患者血清及支气管肺泡灌洗液中KL-6水平及其意义[J].中华内科杂志, 2007, 46:151-152. doi:  10.3760/j.issn:0578-1426.2007.02.023
    [20] Hamai K, Iwamoto H, Ishikawa N, et al.Comparative Study of Circulating MMP-7, CCL18, KL-6, SP-A, and SP-D as Disease Markers of Idiopathic Pulmonary Fibrosis[J]. Dis Markers, 2016, 17:4759040-4759048. http://www.ncbi.nlm.nih.gov/pubmed/27293304
    [21] Sokai A, Tanizawa K, Handa T, et al.Importance of serial changes in biomarkers in idiopathic pulmonary fibrosis[J]. ERJ Open Res, 2017, 3:30. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5576222/
    [22] Yokoyama A, Kondo K, Nakajima M, et al. Prognostic value of circulating KL-6 in idiopathic pulmonary fibrosis[J]. Respirology, 2006, 11:164-168. doi:  10.1111/j.1440-1843.2006.00834.x
    [23] Ohshimo S, Ishikawa N, Horimasu Y, et al.Baseline KL-6 predicts increased risk for acute exacerbation of idiopathic pulmonary fibrosis[J].Respir Med, 2014, 108:1031-1039. doi:  10.1016/j.rmed.2014.04.009
    [24] Qiu M, Chen Y, Ye Q. Risk factors for acute exacerbation of idiopathic pulmonary fibrosis:A systematic review and meta-analysis[J]. Clin Respir J, 2018, 12:1084-1092. doi:  10.1111/crj.12631
    [25] Oguz EO, Kucuksahin O, Turgay M, et al. Association of serum KL-6 levels with interstitial lung disease in patients with connective tissue disease:a cross-sectional study[J]. Clin Rheumatol, 2016, 35:663-666. doi:  10.1007/s10067-015-3167-8
    [26] Nakajima H, Harigai M, Hara M, et al. KL-6 as a novel serum marker for interstitial pneumonia associated with collagen diseases[J]. J Rheumatol, 2000, 27:1164-1170. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=689f1a6522655569b0cfaadf4a8180ad
    [27] 王冉冉, 田美伊, 杨金水, 等.血清KL-6水平对评价结缔组织病间质性肺疾病作用的研究[J].中国临床医生杂志, 2017, 45:36-40. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zglcys201703012
    [28] Benyamine A, Heim X, Resseguier N, et al. Elevated serum Krebs von den Lungen-6 in systemic sclerosis:a marker of lung fibrosis and severity of the disease[J]. Rheumatol Int, 2018, 38:813-819. doi:  10.1007/s00296-018-3987-3
    [29] Kumánovics G, Gorbe E, Minier T, et al. Follow-up of serum KL-6 lung fibrosis biomarker levels in 173 patients with systemic sclerosis[J]. Clin Exp Rheumatol, 2014, 32:S138-S144. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=4a461e9c7c187a78bd6af3f8de34f52e
    [30] Kuwana M, Shirai Y, Takeuchi T. Elevated Serum Krebs von den Lungen-6 in Early Disease Predicts Subsequent Deterioration of Pulmonary Function in Patients with Systemic Sclerosis and Interstitial Lung Disease[J]. J Rheumatol, 2016, 43:1825-1831. doi:  10.3899/jrheum.160339
    [31] Sugiyama Y, Yoshimi R, Tamura M, et al. The predictive prognostic factors for polymyositis/dermatomyositis-associated interstitial lung disease[J]. Arthritis Res Ther, 2018, 20:7. doi:  10.1186/s13075-017-1506-7
    [32] 卢昕, 谢瑶, 王国春.血清KL-6检测在特发性炎性肌病伴肺间质病变诊断中的价值[J].中华风湿病学杂志, 2006, 10:416-419. doi:  10.3760/j:issn:1007-7480.2006.07.009
    [33] Bandoh S, Fujita J, Ohtsuki Y, et al. Sequential changes of KL-6 in sera of patients with interstitial pneumonia associated with polymyositis/dermatomyositis[J]. Ann Rheum Dis, 2000, 59:257-262. doi:  10.1136/ard.59.4.257
    [34] Chen F, Lu X, Shu X. et al. Predictive value of serum markers for the development of interstitial lung disease in patients with polymyositis and dermatomyositis:a comparative and prospective study[J]. Intern Med J, 2015, 6:8. http://www.ncbi.nlm.nih.gov/pubmed/25827843
    [35] Iwata Y, Wada T, Furuichi K, et al. Serum levels of KL-6 reflect disease activity of interstitial pneumonia associated with ANCA related vasculitis[J]. Intern Med, 2001, 40:1093-1097. doi:  10.2169/internalmedicine.40.1093
    [36] Lee YS, Kim HC, Lee BY, et al.The value of biomarkers as predictors of outcome in patients with rheumatoid arthritis-associated usual interstitial pneumonia[J]. Sarcoidosis Vasc Diffuse Lung Dis, 2016, 33:216-223. http://www.ncbi.nlm.nih.gov/pubmed/27758986
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (259) PDF downloads(244) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return